1. Home
  2. SKYE vs VNRX Comparison

SKYE vs VNRX Comparison

Compare SKYE & VNRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Skye Bioscience Inc.

SKYE

Skye Bioscience Inc.

N/A

Current Price

$1.18

Market Cap

6.4M

Sector

Health Care

ML Signal

N/A

Logo VolitionRX Limited

VNRX

VolitionRX Limited

N/A

Current Price

$0.22

Market Cap

6.3M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
SKYE
VNRX
Founded
2012
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.4M
6.3M
IPO Year
2013
2012

Fundamental Metrics

Financial Performance
Metric
SKYE
VNRX
Price
$1.18
$0.22
Analyst Decision
Buy
Buy
Analyst Count
4
5
Target Price
★ $68.00
$13.62
AVG Volume (30 Days)
98.4K
★ 846.0K
Earning Date
11-24-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
★ N/A
N/A
Revenue
N/A
★ $1,727,384.00
Revenue This Year
N/A
$57.67
Revenue Next Year
N/A
$240.52
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
★ 40.04
52 Week Low
$0.26
$0.13
52 Week High
$11.68
$3.26

Technical Indicators

Market Signals
Indicator
SKYE
VNRX
Relative Strength Index (RSI) 44.62 53.35
Support Level $0.26 $0.15
Resistance Level $1.66 $0.72
Average True Range (ATR) 0.20 0.02
MACD -0.00 0.01
Stochastic Oscillator 62.05 76.19

Price Performance

Historical Comparison
SKYE
VNRX

About SKYE Skye Bioscience Inc.

Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.

About VNRX VolitionRX Limited

VolitionRX Ltd is a United States-based epigenetics company that applies its Nucleosomics platform through its subsidiaries to develop simple, easy-to-use, cost-effective blood tests to help diagnose and monitor range of life-altering diseases including some cancers and diseases associated with NETosis. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. The company is focused on human diagnostics and monitoring but also has a subsidiary focused on diagnostics and monitoring.

Share on Social Networks: